Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

被引：0

作者：

Ceraulo, Antony ^{[1
]}

Mint-Mohamed, Aminetou ^{[1
]}

Maucort-Boulch, Delphine ^{[2
]}

Lapillone, Helene ^{[3
]}

Leverger, Guy ^{[4
]}

Paubelle, Etienne ^{[1
]}

Thomas, Xavier ^{[5
]}

Nibourel, Olivier ^{[6
]}

Preudhomme, Claude ^{[6
]}

Castaigne, Sylvie ^{[7
]}

Dombret, Herve ^{[8
]}

Herpe, Lea ^{[9
]}

Ragu, Christine ^{[10
]}

Bertrand, Yves ^{[11
]}

Mortreux, Franck ^{[1
]}

Wattel, Eric ^{[1
]}

机构：

[1] Lyon Univ, Lyon, France

[2] Hospices Civils Lyon, CNRS UMR 5558, Biostatist, Lyon, France

[3] INSERM UMR S938, Paris, France

[4] Trousseau Hosp, Pediat Dept Oncol & Hematol, HUEP, APHP, Paris, France

[5] CHU, Lyon, France

[6] CHRU Lille, Hematol Lab, Lille, France

[7] Hop Mignot, Hematol, Le Chesnay, France

[8] Hopital St Louis, Hematol, Paris, France

[9] Lyon Univ, Pierre Benite, France

[10] Trousseau Hosp, Dept Pediat Hematol & Oncol, Paris, France

[11] Univ Hosp Lyon, Dept Pediat Hematol & Oncol, Lyon, France

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3952.3952

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3952

引用

页数：5

共 50 条

[1] TET2 expression in a cohort of Egyptian acute myeloid leukemia patients
Hamed, Nahla A.
El Halawani, Nabil A.
Kassem, Heba S.
Ayad, Mona W.
Dammag, Enas A.
EGYPTIAN JOURNAL OF HAEMATOLOGY, 2015, 40 (04): : 159 - 165
[2] The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
L Pagano
L Fianchi
M Caira
S Rutella
G Leone
Oncogene, 2007, 26 : 3679 - 3690
[3] Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
Neuberg, Donna S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 3905 - 3906
[4] Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia
van der Heiden, PLJ
Jedema, I
Willemze, R
Barge, RMY
EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (05) : 409 - 413
[5] The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
Pagano, L.
Fianchi, L.
Caira, M.
Rutella, S.
Leone, G.
ONCOGENE, 2007, 26 (25) : 3679 - 3690
[6] TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia
Zhang, Ting-Juan
Zhou, Jing-Dong
Yang, Dong-Qin
Wang, Yu-Xin
Wen, Xiang-Mei
Guo, Hong
Yang, Lei
Lian, Xin-Yue
Lin, Jiang
Qian, Jun
JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (08) : 5838 - 5846
[7] Reduced TET2 expression in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Scopim-Ribeiro, Renata
Machado-Neto, Joao
Campos, Paula de Melo
Favaro, Patricia
Duarte, Adriana S. S.
Visconte, Valeria
Lorand-Metze, Irene
Costa, Fernando Ferreira
Maciejewski, Jaroslaw P.
Tiu, Ramon V.
Olalla Saad, Sara T.
Traina, Fabiola
BLOOD, 2012, 120 (21)
[8] The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
Reem Nabil
Naglaa M. Hassan
Mona S. Abdellateif
Rania M. Gawdat
Samar Sami Elshazly
Molecular Biology Reports, 2023, 50 : 641 - 653
[9] The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
Nabil, Reem
Hassan, Naglaa M.
Abdellateif, Mona S.
Gawdat, Rania M.
Elshazly, Samar Sami
MOLECULAR BIOLOGY REPORTS, 2023, 50 (01) : 641 - 653
[10] The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
Kell, Jonathan
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 377 - 382

← 1 2 3 4 5 →